Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT (PAP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02081092 |
|
Recruitment Status :
Completed
First Posted : March 7, 2014
Last Update Posted : November 1, 2018
|
Sponsor:
Children's Hospital Medical Center, Cincinnati
Information provided by (Responsible Party):
Children's Hospital Medical Center, Cincinnati
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is twofold: to assess routine cat scan (CT) imaging as a biomarker for removal of lipoprotein surfactant via lung lavage (where CT is the gold-standard imaging technique for density quantification), and to utilize a novel UTE MRI protocol to similarly quantify surfactant removal. This study will also serve to generate baseline scanning that may aid in developing analytical tools to evaluate and treat specific lung regions of patients with PAP.
| Condition or disease |
|---|
| Pulmonary Alveolar Proteinosis |
This study will evaluate x-ray CT as a biomarker for surfactant lavage removal and evaluate an UTE-Thrive MRI protocol at CCHMC as an imaging alternative to CT. Potential subjects who meet study criteria will be identified by the Pulmonary physicians at Cincinnati Children's Hospital Medical Center (CCHMC) and University of Cincinnati (UC) through their clinic patients. The study will include two research MRIs (one pre lavage and the second 24 to 72 hours after the first lung lavage) and if there is a clinical CT performed pre lavage, then one research CT will also be performed with the second research MRI. All image analysis will be quantitative. Whole-lung and regional density will be calculated and evaluated before and after lung lavage, for a quantification of changes in density in the left lung and right lung separately. Since the one lung will serve as control, it will allow precise error estimation (which we expect to be quite small and largely related to differences in lung volume). One purpose of this protocol is to further refine and develop ultra-short echo time (UTE) MRI techniques since Pulmonary Alveolar Proteinosis (PAP) patients may have multiple lavage sessions per year. A subject may be eligible to re-enroll to participate multiple times if the total number of research CTs for all enrollments is one or less for that subject.
| Study Type : | Observational |
| Actual Enrollment : | 9 participants |
| Observational Model: | Case-Only |
| Time Perspective: | Prospective |
| Official Title: | Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT |
| Study Start Date : | December 2013 |
| Actual Primary Completion Date : | October 29, 2018 |
| Actual Study Completion Date : | October 29, 2018 |
| Group/Cohort |
|---|
|
Pulmonary Alveolar Proteinosis (PAP)
Patients diagnosis with Pulmonary Alveolar Proteinosis.
|
Primary Outcome Measures :
- Comparing MRI's images pre and post whole lung lavage [ Time Frame: 24 hours before lung lavage and 24-48 hours after lung lavage ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 8 Years to 75 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Patients with Pulmonary Alveolar Proteinosis
Criteria
Inclusion Criteria:
Clinically diagnosed PAP scheduled for lung lavage with double lumen endoscopy.
- Children patients ≥ 8 years of age
- Adult patients ≤ 75 years of age
- Medically stable as per the opinion of Bruce Trapnell, MD or Robert Wood, MD
- Patient and or parent consent obtained
Exclusion Criteria:
- Standard MRI exclusion criteria as set forth by the CCHMC Division of Radiology
- Pregnancy
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02081092
Locations
| United States, Ohio | |
| Cincinnati Children's Hospital Medical Center | |
| Cincinnati, Ohio, United States, 45229 | |
Sponsors and Collaborators
Children's Hospital Medical Center, Cincinnati
Investigators
| Principal Investigator: | Jason Woods, MD | Children's Hospital Medical Center, Cincinnati |
| Responsible Party: | Children's Hospital Medical Center, Cincinnati |
| ClinicalTrials.gov Identifier: | NCT02081092 History of Changes |
| Other Study ID Numbers: |
2013-7051 |
| First Posted: | March 7, 2014 Key Record Dates |
| Last Update Posted: | November 1, 2018 |
| Last Verified: | October 2018 |
Keywords provided by Children's Hospital Medical Center, Cincinnati:
|
PAP Pulmonary Alveolar Proteinosis Pulmonary Patients |
Additional relevant MeSH terms:
|
Pulmonary Alveolar Proteinosis Lung Diseases Respiratory Tract Diseases |